Profile data is unavailable for this security.
About the company
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
- Revenue in USD (TTM)2.01bn
- Net income in USD349.99m
- Incorporated1994
- Employees1.31k
- LocationExelixis Inc1851 Harbor Bay ParkwayALAMEDA 94502United StatesUSA
- Phone+1 (650) 837-7000
- Fax+1 (650) 837-8300
- Websitehttps://www.exelixis.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alkermes Plc | 1.51bn | 457.54m | 4.77bn | 2.10k | 10.84 | 3.74 | 9.36 | 3.16 | 2.67 | 1.69 | 8.78 | 7.74 | 0.6864 | 1.31 | 4.28 | 718,055.30 | 20.83 | 1.34 | 26.98 | 1.74 | 83.31 | 83.32 | 30.34 | 2.12 | 2.61 | -- | 0.184 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
Ultragenyx Pharmaceutical Inc | 481.30m | -585.12m | 4.96bn | 1.28k | -- | 11.46 | -- | 10.30 | -7.29 | -7.29 | 5.95 | 4.69 | 0.3286 | 1.81 | 5.45 | 377,196.70 | -39.94 | -33.35 | -48.51 | -38.30 | 87.15 | 93.13 | -121.57 | -154.71 | 3.39 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
Krystal Biotech Inc | 166.23m | 105.94m | 5.09bn | 229.00 | 48.48 | 6.06 | 45.09 | 30.61 | 3.65 | 3.65 | 5.70 | 29.22 | 0.2076 | -- | -- | 725,908.30 | 13.23 | -11.50 | 14.07 | -12.01 | 93.07 | -- | 63.73 | -492.85 | 9.33 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
Blueprint Medicines Corp | 362.80m | -205.49m | 5.61bn | 638.00 | -- | 17.48 | -- | 15.47 | -3.42 | -3.42 | 5.85 | 5.07 | 0.3141 | 0.8694 | 5.88 | 553,887.00 | -17.79 | -29.92 | -21.66 | -34.06 | 96.19 | -- | -56.64 | -116.65 | 3.65 | -16.38 | 0.5471 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
Ionis Pharmaceuticals Inc | 813.46m | -365.74m | 5.97bn | 927.00 | -- | 20.99 | -- | 7.34 | -2.53 | -2.53 | 5.63 | 1.81 | 0.2873 | 0.4264 | 29.47 | 877,517.80 | -12.92 | -6.30 | -14.43 | -7.44 | 98.58 | 98.75 | -44.96 | -21.23 | 7.51 | -- | 0.8288 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
Cytokinetics, Inc. | 3.13m | -545.28m | 6.67bn | 423.00 | -- | 61.37 | -- | 2,127.93 | -5.37 | -5.37 | 0.0309 | 0.9236 | 0.0027 | -- | 6.36 | 7,408.98 | -47.34 | -43.14 | -51.07 | -47.22 | -- | -- | -17,398.82 | -540.47 | -- | -12.85 | 0.8578 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
Nuvalent Inc | 0.00 | -173.59m | 6.85bn | 115.00 | -- | 10.66 | -- | -- | -2.78 | -2.78 | 0.00 | 9.84 | 0.00 | -- | -- | 0.00 | -31.08 | -- | -32.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
Viking Therapeutics Inc | 0.00 | -96.75m | 7.20bn | 28.00 | -- | 7.81 | -- | -- | -0.9379 | -0.9379 | 0.00 | 8.31 | 0.00 | -- | -- | 0.00 | -14.36 | -21.91 | -14.78 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
Halozyme Therapeutics, Inc. | 873.30m | 337.29m | 7.50bn | 373.00 | 22.94 | 25.87 | 17.89 | 8.58 | 2.58 | 2.58 | 6.68 | 2.29 | 0.4621 | 1.20 | 3.79 | 2,341,298.00 | 17.85 | 18.22 | 19.11 | 21.97 | 79.95 | 79.05 | 38.62 | 39.36 | 6.21 | -- | 0.8385 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
Exelixis Inc | 2.01bn | 349.99m | 7.60bn | 1.31k | 22.83 | 3.59 | 20.20 | 3.78 | 1.17 | 1.17 | 6.54 | 7.43 | 0.6809 | 3.23 | 6.40 | 1,537,386.00 | 11.83 | 8.86 | 13.38 | 9.91 | 96.06 | 96.30 | 17.38 | 15.43 | 4.21 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
Revolution Medicines Inc | 742.00k | -519.21m | 7.90bn | 443.00 | -- | 4.84 | -- | 10,652.67 | -3.65 | -3.65 | 0.0051 | 9.77 | 0.0005 | -- | 0.5912 | 1,962.96 | -36.03 | -29.76 | -38.48 | -32.59 | -- | -- | -69,973.99 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
Tempus AI Inc | 595.57m | -790.20m | 8.17bn | 2.30k | -- | 83.15 | -- | 13.72 | -8.23 | -8.23 | 4.34 | 0.6367 | -- | -- | -- | -- | -- | -- | -- | -- | 51.85 | -- | -121.04 | -- | 3.52 | -28.75 | 0.8183 | -- | 65.85 | -- | 20.35 | -- | -- | -- |
Legend Biotech Corp (ADR) | 455.99m | -285.01m | 9.04bn | 2.20k | -- | 7.76 | -- | 19.83 | -1.57 | -1.57 | 2.51 | 6.33 | 0.2446 | 10.63 | 32.42 | 253,328.30 | -15.29 | -37.71 | -17.63 | -47.19 | 60.28 | -- | -62.50 | -286.51 | 4.78 | -- | 0.2263 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
Charles River Lbrtrs ntrntl Inc | 4.08bn | 431.79m | 9.85bn | 20.00k | 22.78 | 2.64 | 12.68 | 2.42 | 8.37 | 8.37 | 78.94 | 72.13 | 0.5188 | 8.23 | 5.22 | 203,888.80 | 5.67 | 6.46 | 6.52 | 7.62 | 35.98 | 36.99 | 10.93 | 11.58 | 1.21 | 4.97 | 0.39 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 30.37m | 10.43% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 29.30m | 10.06% |
Farallon Capital Management LLCas of 06 May 2024 | 26.77m | 9.19% |
Renaissance Technologies LLCas of 30 Jun 2024 | 15.16m | 5.21% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 13.08m | 4.49% |
LSV Asset Managementas of 30 Jun 2024 | 5.76m | 1.98% |
Geode Capital Management LLCas of 30 Jun 2024 | 5.17m | 1.77% |
JPMorgan Investment Management, Inc.as of 31 Mar 2024 | 4.85m | 1.67% |
Dimensional Fund Advisors LPas of 30 Jun 2024 | 4.48m | 1.54% |
Stephens Investment Management Group LLCas of 30 Jun 2024 | 3.88m | 1.33% |